Partner Interview
Published December 8, 2022
10x Genomics & Single Cell Sequencing
inpractise.com/articles/10x-genomics-and-single-cell-sequencing
Executive Bio
Former Director at 10x Genomics
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
80 plus.
That's in line. I wish I knew what they were selling it at, but it is impressive they pre-sold 100. I've always believed 10X was operating from a position of strength and playing offense in single cell, but they are playing a different sport with spatial. NanoString beat them to market, so did Vizgen eventually, and Resolve is making noise. This is a crowded, competitive landscape which includes Akoya, so if that instrument is going to be expensive, far less customers will buy multiple platforms. In some ways, it was a race to lock in the heavy hitter customers. I suspect those 100 instruments were offered at deep discounts to ensure their instrument was on the floor and not Vizgen's. That instrument is not currently available so they probably sacrificed margin to get share, otherwise they would miss the boat because the launch is way behind schedule.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

10x Genomics, Azenta & Next-Gen Sequencing
Former Field Scientist at GENEWIZ and Mission Bio

Bio-Rad: Switching Costs and Competitive Dynamics in Single-Cell & Digital PCR
Former Director at Bio-Rad Laboratories

BioLife Solutions: Stirling Ultracold, Cold Storage & Strategic Review
Former President at BioLife Solutions

AMZN, ServiceNow, Atlassian, DDOG, Masimo, CACC, 10x, FDM, Alphawave
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.